← 產業報告目錄
mRNA 2.0 Market Share & Trends Analysis Report, By Technology (Self-Amplifying mRNA (saRNA), Optimized Non-Amplifying mRNA, Circular RNA (circRNA), Programmable/Logic-Gated mRNA), By Application (Infectious Disease Vaccines, Oncology, Rare & Genetic Diseases, Autoimmune & Inflammatory Diseases, Cardiovascular & Metabolic), By End-User, By Region, and Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-29頁數 180報告編號 INSIGHTACE-b524887015
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The global mRNA 2.0 Market is expected to surge at a compound annual growth rate of 12.8% throughout the 2025–2034 forecast period. MRNA 2.0 covers "mRNA 2.0" involves reshaping how healthcare entities approach this space.
Several factors contribute to this trajectory, including heightened need next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region expected to deliver the strongest growth trajectory through the forecast period, underpinned by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global mRNA 2.0 Market Snapshot
Chapter 4. Global mRNA 2.0 Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.9. Use/impact of AI on mRNA 2.0 Market Industry Trends
4.10. Global mRNA 2.0 Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. mRNA 2.0 Market Segmentation 1: By Technology, Estimates & Trend Analysis
5.1. Market Share by Technology, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Technology:
5.2.1. Self-Amplifying mRNA (saRNA)
5.2.2. Optimized Non-amplifying mRNA
5.2.3. Circular RNA (circRNA)
5.2.4. Programmable/Logic-Gated mRNA
Chapter 6. mRNA 2.0 Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Infectious Disease Vaccines
6.2.2. Oncology
6.2.3. Rare & Genetic Diseases
6.2.4. Autoimmune & Inflammatory Diseases
6.2.5. Cardiovascular & Metabolic
Chapter 7. mRNA 2.0 Market Segmentation 3: By End-User, Estimates & Trend Analysis
7.1. Market Share by End-User, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User:
7.2.1. Hospitals & Clinics
7.2.2. Research Institutions
7.2.3. Biopharmaceutical Companies
Chapter 8. mRNA 2.0 Market Segmentation 5: Regional Estimates & Trend Analysis
8.1. Global mRNA 2.0 Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
8.2.3. North America mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.2.4. North America mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
8.3. Europe
8.3.1. Europe mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
8.3.3. Europe mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.3.4. Europe mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
8.4.3. Asia Pacific mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.4.4. Asia Pacific mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
8.5. Latin America
8.5.1. Latin America mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
8.5.3. Latin America mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.5.4. Latin America mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
8.6.3. Middle East & Africa mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.6.4. Middle East & Africa mRNA 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Moderna
9.2.1.1. Business Overview
9.2.1.2. Key Technology/Service Overview
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. BioNTech
9.2.3. Pfizer
9.2.4. CureVac
9.2.5. Arcturus Therapeutics
9.2.6. GSK
9.2.7. AstraZeneca
9.2.8. Merck
9.2.9. Orna Therapeutics
9.2.10. Strand Therapeutics
9.2.11. ReCode Therapeutics
9.2.12. Abogen Biosciences
9.2.13. Nutcracker Therapeutics
9.2.14. Gritstone Bio
9.2.15. Vertex Pharmaceuticals
9.2.16. Ethris
9.2.17. Ziphius Vaccines
9.2.18. Replicate Bioscience
9.2.19. Laronde (Senda Biosciences)
9.2.20. CircBio
9.2.21. Anima Biotech
9.2.22. HDT Bio
9.2.23. VaxEquity
9.2.24. Voltron Therapeutics
9.2.25. Chimeron Bio
9.2.26. MiNA Therapeutics
9.2.27. Acuitas Therapeutics
9.2.28. Evox Therapeutics
9.2.29. DSP
9.2.30. eTheRNA
9.2.31. Kernal Biologics
9.2.32. CSL
9.2.33. Esphera SynBio
9.2.34. Others
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們